In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer at Amolyt Pharma shares his views on the data from the P-I trial of AZP-3601 for the treatment of HypoparathyroidismShots:The P-I trial evaluates the safety, tolerability, PK, PD, and preliminary efficacy of AZP-3601 in 102 healthy volunteers including 52 in the SAD and 50 in the MAD cohorts…